Keyword: science

The continuous operation of Egis is vital

The quality of life of millions depends on the availability of our medicines. Egis is one of the leading generic pharmaceutical companies in Central Easter Europe. We produce approximately 170 million boxes of drugs, 700 tonnes of active pharmaceutical ingredients, 5 billion tablets, capsules annually. Our products are available in 65 countries, and annually more than 30 million patients’ recovery depends on Egis Group’s continuous operation.


Strategic cooperation agreement between Semmelweis University and Egis

The Semmelweis University and Egis Pharmaceuticals PLC have agreed on an even closer cooperation than before. Our common goal is to further raise the standards of pharmaceutical R+D as well as pharmacist and doctor training by making use of the synergies in each other’s activities. As a result of the agreement, new health industrial innovations can be launched and the Semmelweis University can be extended with more practical educational and training elements that also meet the needs of the Hungarian pharmaceutical industry.


Egis Strengthens European Presence in the Biosimilar Area

Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.

WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox